Description
TESA + IPA Research Blend (11 mg | 6 mg)
This dual-action peptide formulation combines Tesamorelin (TESA) and Ipamorelin (IPA) in a precise ratio designed for synergistic laboratory evaluation of growth hormone axis modulation.
Composition & Specs
-
Tesamorelin (11 mg): A stabilized GHRH (Growth Hormone Releasing Hormone) analog.
-
Ipamorelin (6 mg): A selective GHSR (Growth Hormone Secretagogue Receptor) agonist.
-
Purity: ≥98% as verified by HPLC.
-
Format: Lyophilized powder for reconstitution.
Research Objectives
-
Synergistic Signaling: Investigating the concurrent stimulation of the pituitary gland via two distinct pathways (GHRH receptor and Ghrelin receptor).
-
Metabolic Studies: Evaluating impacts on adipose tissue distribution and lipid metabolism.
-
Cellular Repair: Analyzing the blend’s influence on IGF-1 secretion and systemic regenerative markers.
Disclaimer
RESEARCH USE ONLY. This product is a laboratory chemical intended solely for scientific research and development. It is not for human or veterinary use, nor is it intended for clinical, diagnostic, or therapeutic purposes. This substance has not been approved for safety or efficacy in humans by the FDA or any other regulatory authority. All handling must be performed by qualified professionals using appropriate safety protocols. Use of this product in a manner inconsistent with its labeling is strictly prohibited.
